How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?

Authors

  • Claire F. Snyder PhD,

    Corresponding author
    1. Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
    2. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland
    3. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    • Department of Medicine, Johns Hopkins School of Medicine, 624 N. Broadway, Room 657, Baltimore, MD 21205
    Search for more papers by this author
    • Fax: (410) 955-0470

  • Kevin D. Frick PhD,

    1. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    Search for more papers by this author
  • Amanda L. Blackford ScM,

    1. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • Robert J. Herbert,

    1. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
    Search for more papers by this author
  • Bridget A. Neville MPH,

    1. Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for more papers by this author
  • Michael A. Carducci MD,

    1. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • Craig C. Earle MD, MSc

    1. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    Search for more papers by this author

Abstract

BACKGROUND.

Data regarding costs of prostate cancer treatment are scarce. This study investigates how initial treatment choice affects short-term and long-term costs.

METHODS.

This retrospective, longitudinal cohort study followed prostate-cancer cases diagnosed in 2000 for 5 years using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Men age ≥66 years, in Medicare fee for service, diagnosed with clinically localized prostate cancer in 2000 while residing in a SEER region, were matched to noncancer controls using age, sex, race, region, comorbidity, and survival. On the basis of treatment received during the first 9 months postdiagnosis, patients were assigned to watchful waiting, radiation, hormonal therapy, hormonal + radiation, and surgery (may have received other treatments). Incremental costs for prostate cancer were the difference in costs for prostate cancer cases versus matched controls. Costs were divided into initial treatment (months −1 to 12), long-term (each 12 months thereafter), and total (months −1 to 60). Sensitivity analyses excluded the last 12 months of life.

RESULTS.

A total of 13,769 prostate-cancer cases were matched to 13,769 noncancer controls. Watchful waiting had the lowest initial treatment ($4270) and 5-year total costs ($9130). Initial treatment costs were highest for hormonal + radiation ($17,474) and surgery ($15,197). At $26,896, 5-year total costs were highest for hormonal therapy only followed by hormonal + radiation ($25,097) and surgery ($19,214). After excluding the last 12 months of life, total costs were highest for hormonal + radiation ($23,488) and hormonal therapy ($23,199).

CONCLUSIONS.

Patterns of costs vary widely based on initial treatment. These data can inform patients and clinicians considering treatment options and policy makers interested in patterns of costs. Cancer 2010. © 2010 American Cancer Society.

Ancillary